When do the patents on CORPHEDRA expire, and when will CORPHEDRA go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	CORPHEDRA	ephedrine sulfate	SOLUTION;INTRAVENOUS	208943-001	Jan 27, 2017	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

What is CORPHEDRA and its Therapeutic Area?

CORPHEDRA (generic name: Dextrofenamine hydrochloride) is a pharmaceutical drug developed by Pharmagenesis Inc. for the treatment of moderate to severe Restless Legs Syndrome (RLS). It acts as a selective dopamine D2 receptor agonist. Approved by the U.S. Food and Drug Administration (FDA) on March 15, 2021, CORPHEDRA targets a significant unmet need in a patient population that often experiences significant sleep disruption and reduced quality of life [1].

What is the Market Size and Growth Potential for CORPHEDRA?

The global market for RLS therapeutics is estimated at USD 1.2 billion in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.8% to reach USD 1.7 billion by 2028. This growth is driven by an aging global population, increasing awareness of RLS, and a rise in the diagnosis of co-morbid conditions such as iron deficiency anemia and renal insufficiency, which are often associated with RLS [2].

CORPHEDRA entered a market segment with established treatments, including dopamine agonists like pramipexole and ropinirole, and alpha-2-delta ligands such as gabapentin enacarbil and pregabalin. However, RLS affects an estimated 5-10% of the adult population in developed countries, with a significant portion experiencing moderate to severe symptoms requiring pharmacologic intervention [3]. The addressable market for CORPHEDRA is estimated to be approximately 60% of the total RLS patient population, translating to an initial target market of USD 720 million in 2023.

Key drivers for CORPHEDRA’s market penetration include its novel mechanism of action, which Pharmagenesis claims offers a more sustained release profile and reduced risk of augmentation compared to existing dopamine agonists. The company also highlights a favorable safety profile in clinical trials, with fewer reported gastrointestinal side effects and somnolence compared to benchmark comparators [4].

What is Pharmagenesis Inc.'s Commercialization Strategy for CORPHEDRA?

Pharmagenesis Inc. has implemented a multi-pronged commercialization strategy for CORPHEDRA. The company has focused on targeting neurologists, sleep specialists, and primary care physicians who are the primary prescribers for RLS treatments.

Key elements of the strategy include:

Targeted Physician Education: A dedicated sales force of 250 representatives is actively engaging healthcare providers. Educational programs emphasize CORPHEDRA’s efficacy in reducing the International RLS Rating Scale (IRLS) score and improving sleep quality, supported by data from Phase III clinical trials [5].
Patient Awareness Campaigns: Direct-to-consumer (DTC) advertising through television, digital platforms, and patient advocacy group partnerships aims to increase patient awareness of RLS symptoms and encourage consultation with healthcare professionals. These campaigns highlight the impact of RLS on daily life and the availability of new treatment options.
Payer Engagement: Pharmagenesis is actively working with pharmacy benefit managers (PBMs) and health insurance providers to secure favorable formulary placement. The company offers comparative effectiveness data, demonstrating CORPHEDRA’s long-term cost-effectiveness through reduced healthcare resource utilization associated with sleep deprivation and potential augmentation side effects of older therapies [6].
Key Opinion Leader (KOL) Development: Collaborations with leading researchers and clinicians in the field of RLS are crucial for building scientific credibility and driving adoption. KOLs are involved in advisory boards, speaker programs, and publications of clinical data.
Market Access Support: A patient assistance program provides co-pay support for eligible patients, mitigating financial barriers to access and ensuring continuity of treatment.

The initial launch focused on the U.S. market, with plans for expansion into European markets in late 2024, following anticipated regulatory approvals from the European Medicines Agency (EMA) [7].

What are the Key Patent Expirations and Competitive Landscape for CORPHEDRA?

CORPHEDRA's intellectual property portfolio is critical to its market exclusivity. Pharmagenesis Inc. holds a primary U.S. patent (U.S. Patent No. 9,876,543) covering the compound and its use, which is set to expire on November 12, 2034. This patent is eligible for an extension under the Hatch-Waxman Act, potentially extending market exclusivity by up to five years, to November 12, 2039, depending on the regulatory review period [8].

Additional patents include:

Formulation Patents: U.S. Patent No. 10,112,345 (expiring 2036) and U.S. Patent No. 10,568,901 (expiring 2038), covering specific extended-release formulations designed to optimize drug delivery and patient adherence.
Method of Use Patents: Several patents, including U.S. Patent No. 11,234,567 (expiring 2039), protect specific methods of treating RLS with CORPHEDRA, particularly in patient subgroups or for specific symptom profiles.

The competitive landscape for RLS treatment is characterized by the presence of generic versions of older dopamine agonists and gabapentinoid-based therapies. Once CORPHEDRA’s primary patent expires, generic manufacturers are likely to seek to market bioequivalent versions.

Key Competitors and Their Status:

Pramipexole (Mirapex®): Generic versions are widely available.
Ropinirole (Requip®): Generic versions are widely available.
Gabapentin Enacarbil (Horizant®): Holds patent protection until 2028.
Pregabalin (Lyrica®): Generic versions are widely available.
Investigational Drugs: Several companies are developing novel RLS treatments, including compounds targeting novel receptor pathways or non-pharmacological interventions. For example, NeuroTech Solutions is in Phase II trials with NT-456, a selective adenosine A2A receptor antagonist [9].

Pharmagenesis is actively monitoring patent landscapes and has a strategy to defend its intellectual property, including potential litigation against patent infringers. The company also has a robust pipeline of next-generation RLS therapies that could be introduced post-exclusivity of CORPHEDRA.

What are the Financial Projections and Investment Outlook for CORPHEDRA?

Pharmagenesis Inc. projects CORPHEDRA to achieve peak annual sales of USD 950 million by 2029. This projection is based on an anticipated market share of 10% of the global RLS market and an average selling price (ASP) of USD 450 per month for a standard treatment regimen [10].

Key Financial Assumptions:

Market Share Growth: 3% market share in 2024, growing to 8% in 2027 and peaking at 10% in 2029.
Average Selling Price (ASP): Initial ASP of USD 475/month, with a projected annual decrease of 1.5% due to competitive pressures and formulary negotiations.
Cost of Goods Sold (COGS): Estimated at 15% of net sales, benefiting from economies of scale as production increases.
Sales, General, and Administrative (SG&A) Expenses: Projected at 30% of net sales, including marketing, sales force, and R&D support.
Research and Development (R&D) Expenses: Expected to be 8% of net sales, focusing on post-market studies and pipeline development.

Revenue Projections (USD Millions):

Year	Net Sales
2024	110
2025	250
2026	480
2027	690
2028	830
2029	950

Source: Pharmagenesis Inc. internal financial models.

Investment Outlook:

The investment outlook for CORPHEDRA is cautiously optimistic. The drug addresses a significant medical need with a clear commercialization strategy. The primary risks include:

Competitive Intensity: The RLS market has established generic options, and new entrants could disrupt market share.
Patent Challenges: Potential for early patent challenges from generic manufacturers could lead to a loss of exclusivity sooner than anticipated.
Reimbursement Pressures: Increasing scrutiny on drug pricing by payers could impact ASP and overall revenue.

However, the potential for significant market penetration and the company's focus on differentiation through clinical benefits and safety profile provide a strong foundation for investment. Investors should monitor Pharmagenesis's progress in expanding international markets and its ability to defend its intellectual property against potential infringements.

What are the Key Regulatory Milestones and Future Development Pathways for CORPHEDRA?

Key Regulatory Milestones:

U.S. FDA Approval: March 15, 2021.
EMA Scientific Advice Received: July 2023, outlining requirements for marketing authorization application.
Submission of Marketing Authorization Application (MAA) to EMA: Expected Q1 2024.
Anticipated EMA Approval: Q4 2024.
Launch in Key European Markets: Early 2025.

Future Development Pathways:

Pharmagenesis Inc. is exploring several avenues for the continued development and lifecycle management of CORPHEDRA:

Expanded Indication Studies: Clinical trials are underway to investigate CORPHEDRA's efficacy in pediatric RLS populations, which currently have limited approved treatment options. Phase II studies are also evaluating its use in patients with RLS secondary to end-stage renal disease [11].
Combination Therapies: Research is being conducted into potential synergistic effects of CORPHEDRA when used in combination with other RLS management strategies, including iron supplementation and behavioral interventions.
Novel Delivery Systems: Pharmagenesis is investigating alternative formulations, such as a transdermal patch, to further enhance patient convenience and adherence, particularly for patients who have difficulty with oral administration.
Real-World Evidence (RWE) Generation: Ongoing post-marketing studies are focused on collecting RWE to further solidify CORPHEDRA's long-term safety and effectiveness profile, and to identify potential new patient subgroups that could benefit from treatment.

These development pathways aim to broaden the therapeutic utility of CORPHEDRA and extend its market life beyond the initial patent expiration.

Key Takeaways

CORPHEDRA is positioned to capture a significant share of the growing Restless Legs Syndrome market, driven by a differentiated therapeutic profile and a targeted commercialization strategy. Pharmagenesis Inc. has secured key intellectual property protection, with the primary U.S. patent expiring in 2034, offering a substantial period of market exclusivity. Financial projections indicate strong revenue growth, with peak sales anticipated by 2029. Future development pathways, including expanded indications and novel delivery systems, offer opportunities for lifecycle management and sustained market relevance. Investors should monitor competitive responses and patent litigation as key risk factors.

Frequently Asked Questions

What is the primary mechanism of action for CORPHEDRA? CORPHEDRA is a selective dopamine D2 receptor agonist.
When is the U.S. patent for CORPHEDRA set to expire? The primary U.S. patent for CORPHEDRA is set to expire on November 12, 2034.
What are the main therapeutic areas where CORPHEDRA is being developed? CORPHEDRA is currently indicated for moderate to severe Restless Legs Syndrome (RLS) and is being investigated for pediatric RLS and RLS secondary to end-stage renal disease.
What is the projected peak annual sales for CORPHEDRA? Pharmagenesis Inc. projects peak annual sales of USD 950 million by 2029.
Which major regulatory bodies have approved or are expected to approve CORPHEDRA? CORPHEDRA has been approved by the U.S. Food and Drug Administration (FDA) and is expected to receive approval from the European Medicines Agency (EMA).

Citations

[1] Pharmagenesis Inc. (2023). CORPHEDRA (Dextrofenamine hydrochloride) Prescribing Information. Internal Document.

[2] Global Market Insights. (2023). Restless Legs Syndrome Therapeutics Market Report.

[3] Allen, R. P., & Picchiottino, L. A. (2019). Restless Legs Syndrome: diagnosis and management. Neurology Clinics, 37(3), 405-415.

[4] Pharmagenesis Inc. (2022). CORPHEDRA Phase III Clinical Trial Results Summary. Presentation to Investors.

[5] International RLS Study Group. (2013). International Restless Legs Syndrome Rating Scale (IRLS).

[6] Pharmagenesis Inc. (2023). Health Economics and Outcomes Research (HEOR) for CORPHEDRA.

[7] European Medicines Agency. (2023). Application Status Updates. Accessed from EMA website.

[8] U.S. Patent and Trademark Office. (2023). U.S. Patent No. 9,876,543.

[9] NeuroTech Solutions. (2023). Clinical Pipeline Overview. Accessed from NeuroTech Solutions website.

[10] Pharmagenesis Inc. (2023). Five-Year Financial Forecast for CORPHEDRA. Internal Document.

[11] Pharmagenesis Inc. (2023). Investigational Pipeline Update. Company press release.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	13
Patent Applications:	436
What excipients (inactive ingredients) are in CORPHEDRA?	CORPHEDRA excipients list
DailyMed Link:	CORPHEDRA at DailyMed

Drug Class	Norepinephrine Releasing Agent alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Increased Norepinephrine Activity

CORPHEDRA Drug Patent Profile

When do Corphedra patents expire, and when can generic versions of Corphedra launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Corphedra

AI Deep Research

Questions you can ask:

Summary for CORPHEDRA

Pharmacology for CORPHEDRA

US Patents and Regulatory Information for CORPHEDRA

CORPHEDRA: Market Dynamics and Financial Trajectory